CARDIOVASCULAR RISK FACTORS IN WOMEN WITH PCOS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 多囊卵巢综合征(PCOS)是一种复杂的综合征，影响5-10%的绝经前妇女，已知与血脂紊乱、胰岛素抵抗、糖耐量受损和高血压相关的风险。这些研究人员假设，与没有PCOS的体重匹配的对照组相比，患有PCOS的肥胖女性将有更高的炎症标志物水平和动脉粥样硬化的证据(由更高的冠状动脉钙化评分确定)。他们将把这些因素与该人群中代谢综合征的存在联系起来。他们还假设，二甲双胍，一种常用于多囊卵巢综合征妇女的药物，其胰岛素敏化和排卵诱导作用，将降低肥胖多囊卵巢综合征妇女的炎症标志物水平。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Polycystic ovarian syndrome (PCOS) is a complex syndrome affecting 5-10% of premenopausal women, with known associated risks of lipid disorders, insulin resistance, impaired glucose tolerance and hypertension. These investigators hypothesize that obese women with PCOS will have increased levels of inflammatory markers and evidence of atherosclerosis (as determined by higher coronary artery calcium scores) than weight-matched controls without PCOS. They will correlate these factors with the presence of the metabolic syndrome within this population. They also hypothesize that metformin, a drug commonly used in women with PCOS for its insulin sensitization and ovulation induction effects, will reduce levels of inflammatory markers in the obese PCOS women.